Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.

Inclusion criteria

• Patients who have given their written informed consent. If it is considered that obtaining written consent could constitute a factor for the transmission of the disease (given the high contagiousness of the SARS-Cov-2 virus), it will be permitted to obtain duly justified verbal consent in the patient's medical history.
• Clinical diagnosis or confirmed by analytical tests (PCR of viral RNA or detection of antiSARS-Cov-2 antibodies) that requires care in hospital and that are grade 3 or 4 of the WHO 7-point ordinal scale of severity categorization for COVID.
• Platelets> 50,000 / uL, neutrophils> 500 / ul
• Kidney or liver failure is not a contraindication, dose adjustment will be made according to the SmPC
• Women of childbearing potential who are sexually active, not undergoing a hysterectomy or double adnexectomy, should follow the following indications for contraception:

• Negative serum or urine pregnancy test in the 72 hours prior to the start of treatment.
• Use of a medically accepted contraceptive method during: 2 months prior to the start of study treatment, during the study and up to 3 months after the last dose of treatment.

Exclusion criteria

• Documented concomitant severe bacterial or fungal infection
• Infection with HIV, HCV, HBV
• Age <18 years
• Thrombocytopenia <50,000 / uL, Neutropenia <500 / uL
• Women of childbearing age who do not use an effective contraceptive method.
• Pregnant or lactating women.
• Patients who do not want or cannot comply with the protocol.
• Patients with impaired gastrointestinal function or gastric disease that significantly impairs the absorption of ruxolitinib or simvastatin, such as: severe ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, extensive resection (> 1m) of the small intestine or inability to swallow oral medication. Previous partial or total gastrectomy is not an exclusion criterion